Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network

This study is currently recruiting participants.
Verified October 2012 by Vanderbilt-Ingram Cancer Center
Sponsor:
Collaborator:
Addario Lung Cancer Institute (ALCMI)
Information provided by (Responsible Party):
Leora Horn, MD, Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier:
NCT01574300
First received: March 28, 2012
Last updated: October 18, 2012
Last verified: October 2012

March 28, 2012
October 18, 2012
November 2010
January 2017   (final data collection date for primary outcome measure)
Collect, process, store, and distribute for peer-reviewed research studies tumor-related and normal biospecimens from advanced stage lung cancer patients [ Time Frame: 7 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01574300 on ClinicalTrials.gov Archive Site
  • Maintain a centralized, computerized database of all specimens [ Time Frame: 7 years ] [ Designated as safety issue: No ]
    Database would contain uniform and complete demographic, pathologic, and clinical information
  • Facilitate integration of molecular assays and other laboratory studies with clinical patient outcomes [ Time Frame: 7 years ] [ Designated as safety issue: No ]
  • Enable the discovery of novel genes and proteins related to cancer and its therapies [ Time Frame: 7 years ] [ Designated as safety issue: No ]
    Obtain funding from National Institutes of Health based on use of the biorepository
Same as current
Not Provided
Not Provided
 
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network

The purpose of this study is to facilitate application of the known biomarkers to patients presenting today, and to establish a collection of biospecimens that will be useful for discovering and validating new biomarkers for future use.

Because of the historically poor outcomes of lung cancer patients, suboptimal therapeutic efficacy, and significant side effects of chemotherapy, and the need to choose more efficacious treatment regimens, and patients most likely to benefit from them, there is a need to predict a priori whether an individual patient's tumor will respond to a particular therapeutic agent. However, virtually all lung cancer tumor samples available today are from resection specimens so direct, intra-patient molecular-clinical therapy correlations are impossible.

Without the critical mass of tissue and data necessary to identify optimal molecular targets for lung cancer and drugs active against these targets, new discoveries that offer the only hope of long-term survival for many lung cancer patients remain elusive.

This study facilitates the collection of biospecimens from advanced lung cancer patients and routine determination of a panel of documented clinically significant biomarkers. In addition, it will centrally integrate and standardize research tissue samples with corresponding proteomic, genomic, molecular and clinical data across a multitude of institutions and oncology networks

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Advanced stage lung cancer patients

  • Non-small Cell Lung Cancer Metastatic
  • Small Cell Lung Carcinoma
Other: therapeutic interventions
All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
Biospecimens and biofluids

This is a multi-cohort parallel study in which tumor, plasma and serum samples will be collected prior to the start of any therapeutic intervention for stage IV lung cancer. These biospecimens will be correlated with treatment and clinical data and distributed for peer reviewed research purposes to academic and community centers in the U.S. and Europe.

The biospecimens collected in CASTLE will be analyzed for a panel of biomarkers, currently including:

  • tumor: epidermal growth factor receptor (EGFR), KRAS (Kirsten RAt Sarcoma) gene and EML4-ALK (echinoderm microtubule-associated protein-like 4 - anaplastic lymphoma kinase) translocations, and EGFR, TS (thymidylate synthase), ERCC1 (excision repair cross-complementing 1) and RRM1 (Ribonucleotide Reductase, M1 Subunit) gene expressions
  • serum: proteomics predictive for EGFR-TKI (tyrosine kinase inhibotors)response
Intervention: Other: therapeutic interventions
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
250
January 2017
January 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • M1A or B NSCLC with any number of prior therapies or any stage Small cell Lung Cancer (SCLC) with any number of prior therapies
  • Planned systemic therapy (i.e. intent to treat)
  • Provision of written informed consent for biospecimen storage, broad genetic and proteomic analysis of tumor and normal tissues, without restrictions, AND correlation with outcome data
  • Aged 18 years and over.
  • Measurable or evaluable disease.
  • ECOG performance status of 0-2 with expected survival of at least 3 months.
  • Tumor specimens:
  • Tumor specimens:
  • 4.7.1 First Priority: availability of a minimum of a 1 X 10 mm core fresh frozen tumor, or ≥3 mm diameter spherical pellet from a pleural effusion (≥50% tumor cells), or ≥3 mm diameter spherical pellet from a fine needle aspirate (≥50% tumor cells) from clinically indicated interventional procedures, with no systemic anti-cancer therapy or radiation to all sites of evaluable disease between collection of the biopsy and entry into the study (e.g. if a brain metastasis was radiated but the lung tumor was not, then the latter could still be biopsied and the subject enrolled after radiation therapy of the brain metastasis (and vice versa)).

or

  • Second Priority: availability of paraffin-embedded tumor (via biopsies or pleural effusions) at least 5 X 5 mm (3 X 3 mm for pleural effusions) cross-sectional tumor area, with no systemic anti-cancer therapy or radiation to all sites of evaluable disease between collection of the biopsy and entry into the study; the collection of the paraffin-embedded tissues may have taken place up to 12 months prior to enrollment in CASTLE.
  • Willingness to undergo all study collection procedures and sample analyses including prerequisite baseline molecular testing via ResponseDX: Lung (Response Genetics Inc.) and VeriStrat (Biodesix) - see 6.3 below for details.
  • Exclusion criteria
  • Other co-existing malignancies except for basal cell carcinoma or cervical cancer in situ.
  • Compromise of patient diagnosis or staging if tissue is harvested for research
Both
18 Years and older
No
Contact: Vanderbilt Cancer Center Clinical Trials Information 800-811-8480
United States
 
NCT01574300
THO 09110, CASTLE Study
No
Leora Horn, MD, Vanderbilt-Ingram Cancer Center
Leora Horn, MD
Addario Lung Cancer Institute (ALCMI)
Principal Investigator: Leora Horn, MD Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP